Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The daily Top 10 COVID papers

  Lung Cancer

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 443 articles:
HTML format

Single Articles

    February 2021
  1. ARAUJO LH, Souza BM, Leite LR, Parma SAF, et al
    Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    BMC Cancer. 2021;21:193.
    PubMed     Abstract available

  2. CHEN J, Sun M, Zhou M, Lu R, et al
    Correction to: Associations between I/D polymorphism in the ACE gene and lung cancer: an updated systematic review and a meta-analysis.
    BMC Cancer. 2021;21:192.

  3. ESTER M, Culos-Reed SN, Abdul-Razzak A, Daun JT, et al
    Feasibility of a multimodal exercise, nutrition, and palliative care intervention in advanced lung cancer.
    BMC Cancer. 2021;21:159.
    PubMed     Abstract available

  4. CHEN J, Sun M, Zhou M, Lu R, et al
    Associations between I/D polymorphism in the ACE gene and lung cancer: an updated systematic review and a meta-analysis.
    BMC Cancer. 2021;21:158.
    PubMed     Abstract available

  5. PAZIK M, Michalska K, Zebrowska-Nawrocka M, Zawadzka I, et al
    Clinical significance of HRAS and KRAS genes expression in patients with non-small-cell lung cancer - preliminary findings.
    BMC Cancer. 2021;21:130.
    PubMed     Abstract available

  6. KIDD J, Cassim S, Rolleston A, Chepulis L, et al
    Ha Ora: secondary care barriers and enablers to early diagnosis of lung cancer for Maori communities.
    BMC Cancer. 2021;21:121.
    PubMed     Abstract available

  7. THUREAU S, Marchesi V, Vieillard MH, Perrier L, et al
    Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase II
    BMC Cancer. 2021;21:117.
    PubMed     Abstract available

    January 2021
  8. WAN Y, Yao D, Fang F, Wang Y, et al
    LncRNA WT1-AS downregulates lncRNA UCA1 to suppress non-small cell lung cancer and predicts poor survival.
    BMC Cancer. 2021;21:104.
    PubMed     Abstract available

  9. HAYASHI T, Shimokawa M, Matsuo K, Iihara H, et al
    Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis.
    BMC Cancer. 2021;21:74.
    PubMed     Abstract available

  10. ZHAO K, Wang C, Shi F, Huang Y, et al
    Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
    BMC Cancer. 2021;21:66.
    PubMed     Abstract available

  11. JI G, Bao T, Li Z, Tang H, et al
    Current lung cancer screening guidelines may miss high-risk population: a real-world study.
    BMC Cancer. 2021;21:50.
    PubMed     Abstract available

  12. KU GW, Kang Y, Yu SL, Park J, et al
    LncRNA LINC00240 suppresses invasion and migration in non-small cell lung cancer by sponging miR-7-5p.
    BMC Cancer. 2021;21:44.
    PubMed     Abstract available

  13. KIM SR, Chun SH, Kim JR, Kim SY, et al
    The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    BMC Cancer. 2021;21:19.
    PubMed     Abstract available

  14. HESS LM, Han Y, Zhu YE, Bhandari NR, et al
    Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.
    BMC Cancer. 2021;21:28.
    PubMed     Abstract available

  15. CORRIVEAU S, Pond GR, Tang GH, Goffin JR, et al
    A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer.
    BMC Cancer. 2021;21:14.
    PubMed     Abstract available

    December 2020
  16. LIN H, Zhang G, Zhang XC, Lian XL, et al
    Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees.
    BMC Cancer. 2020;20:1209.
    PubMed     Abstract available

  17. GONG H, Li Y, Yuan Y, Li W, et al
    EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    BMC Cancer. 2020;20:1189.
    PubMed     Abstract available

  18. TSUCHIYA T, Kamohara R, Muraoka M, Nagayasu T, et al
    A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
    BMC Cancer. 2020;20:1192.
    PubMed     Abstract available

  19. ZHU X, Han J, Lan H, Lin Q, et al
    A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
    BMC Cancer. 2020;20:1190.
    PubMed     Abstract available

  20. BRUECKL WM, Ficker JH, Zeitler G
    Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
    BMC Cancer. 2020;20:1185.
    PubMed     Abstract available

  21. BOUCHEZ C, Pluvy J, Soussi G, Nguenang M, et al
    Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors.
    BMC Cancer. 2020;20:1186.
    PubMed     Abstract available

    November 2020
  22. XU L, Xu F, Kong H, Zhao M, et al
    Effects of reduced platelet count on the prognosis for patients with non-small cell lung cancer treated with EGFR-TKI: a retrospective study.
    BMC Cancer. 2020;20:1152.
    PubMed     Abstract available

  23. YU X, Wang Y, Yuan Z, Yu H, et al
    Benefit of dosimetry distribution for patients with multiple brain metastases from non-small cell lung cancer by a Cyberknife stereotactic radiosurgery (SRS) system.
    BMC Cancer. 2020;20:1144.
    PubMed     Abstract available

  24. CHAI M, Shi Q
    The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis.
    BMC Cancer. 2020;20:1121.
    PubMed     Abstract available

  25. WANG B, Wang DQ, Lin MS, Lu SP, et al
    Accumulation of the delivered dose based on cone-beam CT and deformable image registration for non-small cell lung cancer treated with hypofractionated radiotherapy.
    BMC Cancer. 2020;20:1112.
    PubMed     Abstract available

  26. HIGASHIYAMA M, Miyazaki R, Yamamoto H, Anayama T, et al
    Preoperative AminoIndex Cancer Screening (AICS) abnormalities predict postoperative recurrence in patients undergoing curative resection for non-small cell lung cancer.
    BMC Cancer. 2020;20:1100.
    PubMed     Abstract available

  27. XU F, Song J, Xu B, Wang J, et al
    Clinical study of systemic chemotherapy combined with bronchoscopic interventional cryotherapy in the treatment of lung cancer.
    BMC Cancer. 2020;20:1089.
    PubMed     Abstract available

  28. WANG H, Yin Y, Wang R, Huang J, et al
    Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia.
    BMC Cancer. 2020;20:1081.
    PubMed     Abstract available

    October 2020
  29. PARK JY, Lee YJ, Kim T, Lee CY, et al
    Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea.
    BMC Cancer. 2020;20:1040.
    PubMed     Abstract available

  30. HSU YC, Tsai YH, Weng HH, Hsu LS, et al
    Artificial neural networks improve LDCT lung cancer screening: a comparative validation study.
    BMC Cancer. 2020;20:1023.
    PubMed     Abstract available

  31. BATRA A, Sheka D, Kong S, Cheung WY, et al
    Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer.
    BMC Cancer. 2020;20:1004.
    PubMed     Abstract available

  32. LENG D, Yi J, Xiang M, Zhao H, et al
    Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling.
    BMC Cancer. 2020;20:986.
    PubMed     Abstract available

  33. KAIRA K, Mouri A, Kato S, Yoshimura K, et al
    A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
    BMC Cancer. 2020;20:961.
    PubMed     Abstract available

  34. LEI H, Wang K, Jiang T, Lu J, et al
    KIAA0101 and UbcH10 interact to regulate non-small cell lung cancer cell proliferation by disrupting the function of the spindle assembly checkpoint.
    BMC Cancer. 2020;20:957.
    PubMed     Abstract available

  35. TAKEDA Y, Naka G, Yamaguchi Y, Hashimoto M, et al
    Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations.
    BMC Cancer. 2020;20:951.
    PubMed     Abstract available

    September 2020
  36. REZAEI M, Mostafaei S, Aghaei A, Hosseini N, et al
    The association between HPV gene expression, inflammatory agents and cellular genes involved in EMT in lung cancer tissue.
    BMC Cancer. 2020;20:916.
    PubMed     Abstract available

  37. GRIESHOBER L, Graw S, Barnett MJ, Thornquist MD, et al
    AHRR methylation in heavy smokers: associations with smoking, lung cancer risk, and lung cancer mortality.
    BMC Cancer. 2020;20:905.
    PubMed     Abstract available

  38. XU X, Liu Z, Xiong W, Qiu M, et al
    Combined and interaction effect of chlamydia pneumoniae infection and smoking on lung cancer: a case-control study in Southeast China.
    BMC Cancer. 2020;20:903.
    PubMed     Abstract available

  39. GAO W, Liang J, Ye Y, Lu J, et al
    FUT4siRNA augments the chemosensitivity of non-small cell lung cancer to cisplatin through activation of FOXO1-induced apoptosis.
    BMC Cancer. 2020;20:895.
    PubMed     Abstract available

  40. LI L, Yue HC, Han YW, Liu W, et al
    Relationship between the invasion of lymphocytes and cytokines in the tumor microenvironment and the interval after single brachytherapy hypofractionated radiotherapy and conventional fractionation radiotherapy in non-small cell lung Cancer.
    BMC Cancer. 2020;20:893.
    PubMed     Abstract available

  41. JIANG J, Adams HP, Lange M, Siemann S, et al
    Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.
    BMC Cancer. 2020;20:885.
    PubMed     Abstract available

  42. SCHLUCKEBIER L, Caetano R, Garay OU, Montenegro GT, et al
    Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.
    BMC Cancer. 2020;20:875.
    PubMed     Abstract available

  43. PARK HY, Hwang J, Kim DH, Jeon SM, et al
    Lifetime survival and medical costs of lung cancer: a semi-parametric estimation from South Korea.
    BMC Cancer. 2020;20:846.
    PubMed     Abstract available

  44. BAN WH, Yeo CD, Han S, Kang HS, et al
    Impact of smoking amount on clinicopathological features and survival in non-small cell lung cancer.
    BMC Cancer. 2020;20:848.
    PubMed     Abstract available

  45. WANG J, Liu Z, Pang Q, Zhang T, et al
    Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
    BMC Cancer. 2020;20:837.
    PubMed     Abstract available

    August 2020
  46. NAGHIBZADEH-TAHAMI A, Marzban M, Yazdi-Feyzabadi V, Dabiri S, et al
    Is opium use associated with an increased risk of lung cancer? A case-control study.
    BMC Cancer. 2020;20:807.
    PubMed     Abstract available

  47. LI J, Zheng Q, Zhao X, Zhao J, et al
    Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis.
    BMC Cancer. 2020;20:793.
    PubMed     Abstract available

  48. RADES D, Werner EM, Glatzel E, Eggert MC, et al
    Pneumonitis after radiotherapy for lung cancer (PARALUC): an interventional study to create a symptom-based scoring system for identification of patients developing radiation pneumonitis.
    BMC Cancer. 2020;20:785.
    PubMed     Abstract available

  49. LORENZO-LUACES P, Sanchez L, Saavedra D, Crombet T, et al
    Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.
    BMC Cancer. 2020;20:772.
    PubMed     Abstract available

  50. DICKHOFF C, Senan S, Schneiders FL, Veltman J, et al
    Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
    BMC Cancer. 2020;20:764.
    PubMed     Abstract available

  51. JAMIESON L, Forster MD, Zaki K, Mithra S, et al
    Immunotherapy and associated immune-related adverse events at a large UK centre: a mixed methods study.
    BMC Cancer. 2020;20:743.
    PubMed     Abstract available

  52. RAMELOW J, Brooks CD, Gao L, Almiman AA, et al
    The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models.
    BMC Cancer. 2020;20:738.
    PubMed     Abstract available

  53. WU X, Zhang X, Tao L, Chen P, et al
    Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC).
    BMC Cancer. 2020;20:719.
    PubMed     Abstract available

    July 2020
  54. JIA M, Yu S, Yu J, Li Y, et al
    Comprehensive analysis of spread through air spaces in lung adenocarcinoma and squamous cell carcinoma using the 8th edition AJCC/UICC staging system.
    BMC Cancer. 2020;20:705.
    PubMed     Abstract available

  55. CHEN Y, Hu J, Bu F, Zhang H, et al
    Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:707.
    PubMed     Abstract available

  56. OUYANG W, Yu J, Zhou Y, Hu J, et al
    Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer.
    BMC Cancer. 2020;20:699.
    PubMed     Abstract available

  57. ZHAO Y, He JY, Cui JZ, Meng ZQ, et al
    Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
    BMC Cancer. 2020;20:690.
    PubMed     Abstract available

  58. JIA B, Zheng Q, Wang J, Sun H, et al
    A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database.
    BMC Cancer. 2020;20:666.
    PubMed     Abstract available

  59. AYE PS, Tin Tin S, McKeage MJ, Khwaounjoo P, et al
    Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand.
    BMC Cancer. 2020;20:658.
    PubMed     Abstract available

  60. SUN Y, Wu M, Zhou M, Luo X, et al
    Management of medically inoperable and tyrosine kinase inhibitor-naive early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
    BMC Cancer. 2020;20:646.
    PubMed     Abstract available

  61. PAN ST, Zhou J, Yang F, Zhou SF, et al
    Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells.
    BMC Cancer. 2020;20:634.
    PubMed     Abstract available

  62. WRIGHT CM, Halkett G, Carey Smith R, Moorin R, et al
    Sarcoma epidemiology and cancer-related hospitalisation in Western Australia from 1982 to 2016: a descriptive study using linked administrative data.
    BMC Cancer. 2020;20:625.
    PubMed     Abstract available

    June 2020
  63. XU T, Zhang X, Zhang S, Liu C, et al
    Imaging features and prognostic value of (18)F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study.
    BMC Cancer. 2020;20:596.
    PubMed     Abstract available

  64. MA F, Xie Y, Lei Y, Kuang Z, et al
    The microRNA-130a-5p/RUNX2/STK32A network modulates tumor invasive and metastatic potential in non-small cell lung cancer.
    BMC Cancer. 2020;20:580.
    PubMed     Abstract available

  65. KANG DH, Jung SS, Yeo MK, Lee DH, et al
    Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    BMC Cancer. 2020;20:571.
    PubMed     Abstract available

  66. TENG X, Wei L, Han L, Min D, et al
    Establishment of a serological molecular model for the early diagnosis and progression monitoring of bone metastasis in lung cancer.
    BMC Cancer. 2020;20:562.
    PubMed     Abstract available

  67. LAKE M, Shusted CS, Juon HS, McIntire RK, et al
    Black patients referred to a lung cancer screening program experience lower rates of screening and longer time to follow-up.
    BMC Cancer. 2020;20:561.
    PubMed     Abstract available

  68. LIEVERSE RIY, Van Limbergen EJ, Oberije CJG, Troost EGC, et al
    Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
    BMC Cancer. 2020;20:557.
    PubMed     Abstract available

  69. HUANG T, Sun H, Luo X, Zhang X, et al
    Correlation study between flash dual source CT perfusion imaging and regional lymph node metastasis of non-small cell lung cancer.
    BMC Cancer. 2020;20:547.
    PubMed     Abstract available

  70. LIU Q, Huang Y, Chen H, Liu Y, et al
    The development and validation of a radiomic nomogram for the preoperative prediction of lung adenocarcinoma.
    BMC Cancer. 2020;20:533.
    PubMed     Abstract available

  71. LIU Y, Zhu Y, Bai L, Chen F, et al
    Adenocarcinomatous-predominant subtype associated with a better prognosis in adenosquamous lung carcinoma.
    BMC Cancer. 2020;20:520.
    PubMed     Abstract available

  72. KOSHIMUNE S, Kosaka M, Mizuno N, Yamamoto H, et al
    Prognostic value of OCT4A and SPP1C transcript variant co-expression in early-stage lung adenocarcinoma.
    BMC Cancer. 2020;20:521.
    PubMed     Abstract available

  73. CHEN J, Xia J, Huang J, Xu R, et al
    Effect of aspirin on PET parameters in primary non-small cell lung cancer and its relationship with prognosis.
    BMC Cancer. 2020;20:510.
    PubMed     Abstract available

  74. DEVECKA M, Duma MN, Wilkens JJ, Kampfer S, et al
    Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
    BMC Cancer. 2020;20:501.
    PubMed     Abstract available

    May 2020
  75. NILSSEN Y, Brustugun OT, Eriksen MT, Haug ES, et al
    Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.
    BMC Cancer. 2020;20:488.
    PubMed     Abstract available

  76. EL YACOUBI H, Sow ML, Kettani F, Gamra L, et al
    Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study.
    BMC Cancer. 2020;20:479.
    PubMed     Abstract available

  77. SOLARI JIG, Filippi-Chiela E, Pilar ES, Nunes V, et al
    Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
    BMC Cancer. 2020;20:474.
    PubMed     Abstract available

  78. HOWLETT J, Benzenine E, Cottenet J, Foucher P, et al
    Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study.
    BMC Cancer. 2020;20:461.
    PubMed     Abstract available

  79. KESSEL KA, Grosser RCE, Kraus KM, Hoffmann H, et al
    Stereotactic body radiotherapy (SBRT) in patients with lung metastases - prognostic factors and long-term survival using patient self-reported outcome (PRO).
    BMC Cancer. 2020;20:442.
    PubMed     Abstract available

  80. DE MOL M, Visser S, Aerts J, Lodder P, et al
    The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study.
    BMC Cancer. 2020;20:431.
    PubMed     Abstract available

  81. WU X, Yu W, Petersen RH, Sheng H, et al
    A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma.
    BMC Cancer. 2020;20:429.
    PubMed     Abstract available

  82. HU L, Zhang P, Mei Q, Sun W, et al
    Podoplanin is a useful prognostic marker and indicates better differentiation in lung squamous cell cancer patients? A systematic review and meta-analysis.
    BMC Cancer. 2020;20:424.
    PubMed     Abstract available

  83. WAGENER-RYCZEK S, Heydt C, Suptitz J, Michels S, et al
    Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.
    BMC Cancer. 2020;20:408.
    PubMed     Abstract available

  84. KALINAUSKAITE GG, Tinhofer II, Kufeld MM, Kluge AA, et al
    Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases.
    BMC Cancer. 2020;20:404.
    PubMed     Abstract available

  85. BERKOVIC P, Gulyban A, Defraene G, Swenen L, et al
    Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases.
    BMC Cancer. 2020;20:402.
    PubMed     Abstract available

  86. YOON SH, Kim HS, Kim RN, Jung SY, et al
    NAD(P)-dependent steroid dehydrogenase-like is involved in breast cancer cell growth and metastasis.
    BMC Cancer. 2020;20:375.
    PubMed     Abstract available

  87. KEPPENS C, Dequeker EMC, Rouleau E, 't Hart N, et al
    Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples.
    BMC Cancer. 2020;20:366.
    PubMed     Abstract available

  88. WAKUDA K, Yamaguchi H, Kenmotsu H, Fukuda M, et al
    A phase II study of Osimertinib for patients with radiotherapy-naive CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
    BMC Cancer. 2020;20:370.
    PubMed     Abstract available

    April 2020
  89. CHIANG AC, Fernandes AW, Pavilack M, Wu JW, et al
    EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    BMC Cancer. 2020;20:356.
    PubMed     Abstract available

  90. KITAGAWA Y, Osumi H, Shinozaki E, Ota Y, et al
    Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective stud
    BMC Cancer. 2020;20:358.
    PubMed     Abstract available

  91. ZOU Y, Xu L, Tang Q, You Q, et al
    Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
    BMC Cancer. 2020;20:344.
    PubMed     Abstract available

  92. HAZELL SZ, Mai N, Fu W, Hu C, et al
    Hospitalization and definitive radiotherapy in lung cancer: incidence, risk factors and survival impact.
    BMC Cancer. 2020;20:334.
    PubMed     Abstract available

  93. QIN K, Hou H, Liang Y, Zhang X, et al
    Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    BMC Cancer. 2020;20:328.
    PubMed     Abstract available

  94. JIN X, Guan Y, Zhang Z, Wang H, et al
    Microarray data analysis on gene and miRNA expression to identify biomarkers in non-small cell lung cancer.
    BMC Cancer. 2020;20:329.
    PubMed     Abstract available

  95. YAO W, Wang L, Huang H, Li X, et al
    All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells.
    BMC Cancer. 2020;20:315.
    PubMed     Abstract available

  96. SHEILL G, Guinan E, O'Neill L, Normand C, et al
    Preoperative exercise to improve fitness in patients undergoing complex surgery for cancer of the lung or oesophagus (PRE-HIIT): protocol for a randomized controlled trial.
    BMC Cancer. 2020;20:321.
    PubMed     Abstract available

  97. SHAH N, Liu Z, Tallman RM, Mohammad A, et al
    Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.
    BMC Cancer. 2020;20:292.
    PubMed     Abstract available

  98. STEEGHS EMP, Kroeze LI, Tops BBJ, van Kempen LC, et al
    Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
    BMC Cancer. 2020;20:291.
    PubMed     Abstract available

  99. SANO K, Nakadate K, Hanada K
    Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer.
    BMC Cancer. 2020;20:279.
    PubMed     Abstract available

  100. BI N, Liu L, Liang J, Wu S, et al
    Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
    BMC Cancer. 2020;20:278.
    PubMed     Abstract available

  101. HANSEN RN, Zhang Y, Seal B, Ryan K, et al
    Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
    BMC Cancer. 2020;20:276.
    PubMed     Abstract available

  102. DELGADO-GARCIA M, Weynand B, Gomez-Izquierdo L, Hernandez MJ, et al
    Clinical performance evaluation of the Idylla EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.
    BMC Cancer. 2020;20:275.
    PubMed     Abstract available

    March 2020
  103. HARDTSTOCK F, Myers D, Li T, Cizova D, et al
    Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.
    BMC Cancer. 2020;20:260.
    PubMed     Abstract available

  104. XU N, Liu F, Wu S, Ye M, et al
    CHD4 mediates proliferation and migration of non-small cell lung cancer via the RhoA/ROCK pathway by regulating PHF5A.
    BMC Cancer. 2020;20:262.
    PubMed     Abstract available

  105. DING R, Zhu D, He P, Ma Y, et al
    Comorbidity in lung cancer patients and its association with medical service cost and treatment choice in China.
    BMC Cancer. 2020;20:250.
    PubMed     Abstract available

  106. ZHAO J, Xiang C, Zhao R, Guo P, et al
    Clinicopathologic features and genomic analysis of pulmonary blastomatoid carcinosarcoma.
    BMC Cancer. 2020;20:248.
    PubMed     Abstract available

  107. SIEBENHUNER AR, Guller U, Warschkow R
    Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases.
    BMC Cancer. 2020;20:246.
    PubMed     Abstract available

  108. NAWROCKI S, Sugajska A
    Study protocol: watchful observation of patients with limited small cell lung cancer instead of the PCI-prospective, multi-center one-arm study.
    BMC Cancer. 2020;20:231.
    PubMed     Abstract available

  109. MOSS C, Haire A, Cahill F, Enting D, et al
    Guy's cancer cohort - real world evidence for cancer pathways.
    BMC Cancer. 2020;20:187.
    PubMed     Abstract available

  110. TOZUKA T, Kitazono S, Sakamoto H, Yoshida H, et al
    Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
    BMC Cancer. 2020;20:207.
    PubMed     Abstract available

  111. YANG F, Hu M, Chang S, Huang J, et al
    Alteration in the sensitivity to crizotinib by Na(+)/H(+) exchanger regulatory factor 1 is dependent to its subcellular localization in ALK-positive lung cancers.
    BMC Cancer. 2020;20:202.
    PubMed     Abstract available

  112. DIMOU A, Barron G, Merrick DT, Kolfenbach J, et al
    Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma.
    BMC Cancer. 2020;20:177.
    PubMed     Abstract available

    February 2020
  113. LUO P, Yang X, Huang S, Feng S, et al
    Syntenin overexpression in human lung cancer tissue and serum is associated with poor prognosis.
    BMC Cancer. 2020;20:159.
    PubMed     Abstract available

  114. DREVINSKAITE M, Patasius A, Kevlicius L, Mickys U, et al
    Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature.
    BMC Cancer. 2020;20:162.
    PubMed     Abstract available

  115. ADACHI Y, Yanagimura N, Suzuki C, Ootani S, et al
    Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
    BMC Cancer. 2020;20:156.
    PubMed     Abstract available

  116. WANG C, Wu Y, Shao J, Liu D, et al
    Clinicopathological variables influencing overall survival, recurrence and post-recurrence survival in resected stage I non-small-cell lung cancer.
    BMC Cancer. 2020;20:150.
    PubMed     Abstract available

  117. CAI Y, Wu H, Shi X, Dong Y, et al
    Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
    BMC Cancer. 2020;20:148.
    PubMed     Abstract available

  118. DUTTA P, Zhang L, Zhang H, Peng Q, et al
    Unphosphorylated STAT3 in heterochromatin formation and tumor suppression in lung cancer.
    BMC Cancer. 2020;20:145.
    PubMed     Abstract available

  119. GOEBEL C, Louden CL, Mckenna R Jr, Onugha O, et al
    Blood test shows high accuracy in detecting stage I non-small cell lung cancer.
    BMC Cancer. 2020;20:137.
    PubMed     Abstract available

  120. HATTORI Y, Kono Y, Itoh S, Inoue T, et al
    A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer.
    BMC Cancer. 2020;20:115.
    PubMed     Abstract available

  121. LAWRENSON R, Lao C, Brown L, Moosa L, et al
    Management of patients with early stage lung cancer - why do some patients not receive treatment with curative intent?
    BMC Cancer. 2020;20:109.
    PubMed     Abstract available

  122. ZHENG J, Ye X, Liu Y, Zhao Y, et al
    The combination of CTCs and CEA can help guide the management of patients with SPNs suspected of being lung cancer.
    BMC Cancer. 2020;20:106.
    PubMed     Abstract available

  123. TOKUDOME N, Koh Y, Akamatsu H, Fujimoto D, et al
    Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.
    BMC Cancer. 2020;20:103.
    PubMed     Abstract available

  124. KOGO M, Fujimoto D, Hosoya K, Nagata K, et al
    Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.
    BMC Cancer. 2020;20:104.
    PubMed     Abstract available

  125. MORITA M, Tamiya M, Fujimoto D, Tamiya A, et al
    Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
    BMC Cancer. 2020;20:93.
    PubMed     Abstract available

    January 2020
  126. RUIZ-CORDERO R, Ma J, Khanna A, Lyons G, et al
    Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
    BMC Cancer. 2020;20:83.
    PubMed     Abstract available

  127. LIU K, Jiang G, Zhang A, Li Z, et al
    Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
    BMC Cancer. 2020;20:76.
    PubMed     Abstract available

  128. LI X, Zhang W, Yu Y, Zhang G, et al
    CT features and quantitative analysis of subsolid nodule lung adenocarcinoma for pathological classification prediction.
    BMC Cancer. 2020;20:60.
    PubMed     Abstract available

  129. FOWLER H, Belot A, Ellis L, Maringe C, et al
    Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers.
    BMC Cancer. 2020;20:2.
    PubMed     Abstract available

  130. LV Z, Lei T
    Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters.
    BMC Cancer. 2020;20:56.
    PubMed     Abstract available

  131. TIAN H, Shi G, Yang G, Zhang J, et al
    Correction to: Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.
    BMC Cancer. 2020;20:42.
    PubMed     Abstract available

  132. HARLE A, Molassiotis A, Buffin O, Burnham J, et al
    A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need.
    BMC Cancer. 2020;20:9.
    PubMed     Abstract available

  133. GUISIER F, Piton N, Bellefleur M, Delberghe N, et al
    Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.
    BMC Cancer. 2020;20:14.
    PubMed     Abstract available

    December 2019
  134. SUN H, Zhang G, Ai B, Zhang H, et al
    A systematic review: comparative analysis of the effects of propofol and sevoflurane on postoperative cognitive function in elderly patients with lung cancer.
    BMC Cancer. 2019;19:1248.
    PubMed     Abstract available

  135. KISSEL M, Martel-Lafay I, Lequesne J, Faivre JC, et al
    Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
    BMC Cancer. 2019;19:1237.
    PubMed     Abstract available

  136. PALMA DA, Chen H, Bahig H, Gaede S, et al
    Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial.
    BMC Cancer. 2019;19:1206.
    PubMed     Abstract available

  137. GE P, Cao L, Chen X, Jing R, et al
    miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    BMC Cancer. 2019;19:1203.
    PubMed     Abstract available

  138. GUAN J, Luo Z, Xiao Z, Xie Y, et al
    Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report.
    BMC Cancer. 2019;19:1188.
    PubMed     Abstract available

  139. SMOLANDER J, Stupnikov A, Glazko G, Dehmer M, et al
    Comparing biological information contained in mRNA and non-coding RNAs for classification of lung cancer patients.
    BMC Cancer. 2019;19:1176.
    PubMed     Abstract available

  140. WU L, Wang W, Dai M, Li H, et al
    PPARalpha ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis.
    BMC Cancer. 2019;19:1166.
    PubMed     Abstract available

    November 2019
  141. TENG X, Teng X
    First report of pulmonary sclerosing pneomucytoma with malignant transformation in both cuboidal surface cells and stromal round cells: a case report.
    BMC Cancer. 2019;19:1154.
    PubMed     Abstract available

  142. KATSUI K, Ogata T, Watanabe K, Katayama N, et al
    Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis.
    BMC Cancer. 2019;19:1144.
    PubMed     Abstract available

  143. HANSEN MS, Licaj I, Braaten T, Langhammer A, et al
    Smoking related lung cancer mortality by education and sex in Norway.
    BMC Cancer. 2019;19:1132.

  144. SHAO C, Yang F, Qin Z, Jing X, et al
    The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis.
    BMC Cancer. 2019;19:1103.
    PubMed     Abstract available

  145. LI Z, Shen D, Zhang J, Zhang J, et al
    Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis.
    BMC Cancer. 2019;19:1104.
    PubMed     Abstract available

  146. CRAIG DJ, Morrison T, Khuder SA, Crawford EL, et al
    Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
    BMC Cancer. 2019;19:1081.
    PubMed     Abstract available

  147. BOZORGMEHR F, Hommertgen A, Krisam J, Lasitschka F, et al
    Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    BMC Cancer. 2019;19:1074.
    PubMed     Abstract available

  148. CHENG YI, Gan YC, Liu D, Davies MPA, et al
    Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review.
    BMC Cancer. 2019;19:1068.
    PubMed     Abstract available

  149. ZHANG JT, Liu SY, Yan HH, Wu YL, et al
    Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2019;19:1051.
    PubMed     Abstract available

    October 2019
  150. SU L, Chen M, Su H, Dai Y, et al
    Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis.
    BMC Cancer. 2019;19:1023.
    PubMed     Abstract available

  151. CHEN YH, Chen YF, Chen CY, Shih JY, et al
    Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    BMC Cancer. 2019;19:1006.
    PubMed     Abstract available

  152. YAMAGUCHI A, Achmad A, Hanaoka H, Heryanto YD, et al
    Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
    BMC Cancer. 2019;19:1000.
    PubMed     Abstract available

  153. DARBA J, Marsa A
    The cost of lost productivity due to premature lung cancer-related mortality: results from Spain over a 10-year period.
    BMC Cancer. 2019;19:992.
    PubMed     Abstract available

  154. STOPPEK AK, Kebir S, Junker A, Keyvani K, et al
    Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.
    BMC Cancer. 2019;19:995.
    PubMed     Abstract available

  155. CHANG YF, Lim KH, Chiang YW, Sie ZL, et al
    STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers.
    BMC Cancer. 2019;19:959.
    PubMed     Abstract available

  156. YANG Z, Liu C, Wu H, Xie Y, et al
    CSB affected on the sensitivity of lung cancer cells to platinum-based drugs through the global decrease of let-7 and miR-29.
    BMC Cancer. 2019;19:948.
    PubMed     Abstract available

    September 2019
  157. DE HAAN R, van Werkhoven E, van den Heuvel MM, Peulen HMU, et al
    Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
    BMC Cancer. 2019;19:901.
    PubMed     Abstract available

  158. PIAO L, Yang Z, Feng Y, Zhang C, et al
    LETM1 is a potential biomarker of prognosis in lung non-small cell carcinoma.
    BMC Cancer. 2019;19:898.
    PubMed     Abstract available

  159. HO GF, Chai CS, Alip A, Wahid MIA, et al
    Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
    BMC Cancer. 2019;19:896.
    PubMed     Abstract available

  160. LI L, Yan S, Zhang H, Zhang M, et al
    Interaction of hnRNP K with MAP 1B-LC1 promotes TGF-beta1-mediated epithelial to mesenchymal transition in lung cancer cells.
    BMC Cancer. 2019;19:894.
    PubMed     Abstract available

  161. LI Y, Ge D, Gu J, Xu F, et al
    A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    BMC Cancer. 2019;19:886.
    PubMed     Abstract available

    August 2019
  162. BAYAT MOKHTARI R, Baluch N, Morgatskaya E, Kumar S, et al
    Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane.
    BMC Cancer. 2019;19:864.
    PubMed     Abstract available

  163. MOVIA D, Bazou D, Prina-Mello A
    ALI multilayered co-cultures mimic biochemical mechanisms of the cancer cell-fibroblast cross-talk involved in NSCLC MultiDrug Resistance.
    BMC Cancer. 2019;19:854.
    PubMed     Abstract available

  164. LAWRANCE S, Bui C, Mahindra V, Arcorace M, et al
    Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
    BMC Cancer. 2019;19:850.
    PubMed     Abstract available

  165. ISLAM KM, Anggondowati T, Deviany PE, Ryan JE, et al
    Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer.
    BMC Cancer. 2019;19:835.
    PubMed     Abstract available

  166. CHOWDHURY P, Dey P, Ghosh S, Sarma A, et al
    Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
    BMC Cancer. 2019;19:829.
    PubMed     Abstract available

  167. LUCCHETTA M, da Piedade I, Mounir M, Vabistsevits M, et al
    Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response.
    BMC Cancer. 2019;19:824.
    PubMed     Abstract available

  168. KIM KH, Chung C, Kim JM, Lee D, et al
    Clinical significance of atypical protein kinase C (PKCiota and PKCzeta) and its relationship with yes-associated protein in lung adenocarcinoma.
    BMC Cancer. 2019;19:804.
    PubMed     Abstract available

  169. FENG YH, Su YC, Lin SF, Lin PR, et al
    Oct4 upregulates osteopontin via Egr1 and is associated with poor outcome in human lung cancer.
    BMC Cancer. 2019;19:791.
    PubMed     Abstract available

  170. CHEN Y, Wei J, Cai J, Liu A, et al
    Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
    BMC Cancer. 2019;19:793.
    PubMed     Abstract available

  171. CHEN Z, Teng X, Zhang J, Huang K, et al
    Molecular features of lung adenocarcinoma in young patients.
    BMC Cancer. 2019;19:777.
    PubMed     Abstract available

  172. XU S, Wang W, Xu C, Li X, et al
    ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
    BMC Cancer. 2019;19:769.
    PubMed     Abstract available

    July 2019
  173. DJUREINOVIC D, Ponten V, Landelius P, Al Sayegh S, et al
    Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung.
    BMC Cancer. 2019;19:741.
    PubMed     Abstract available

  174. YU H, Sun J, Zhao C, Wang H, et al
    SET domain containing protein 5 (SETD5) enhances tumor cell invasion and is associated with a poor prognosis in non-small cell lung cancer patients.
    BMC Cancer. 2019;19:736.
    PubMed     Abstract available

  175. CHANTHARASAMEE J, Poungvarin N, Danchaivijitr P, Techawatanawanna S, et al
    Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
    BMC Cancer. 2019;19:701.
    PubMed     Abstract available

  176. LIU J, Jin B, Su H, Qu X, et al
    Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    BMC Cancer. 2019;19:702.
    PubMed     Abstract available

  177. GUAN X, Ma CX, Quan JC, Li S, et al
    A clinical model to predict the risk of synchronous bone metastasis in newly diagnosed colorectal cancer: a population-based study.
    BMC Cancer. 2019;19:704.
    PubMed     Abstract available

  178. LI J, Shen C, Wang X, Lai Y, et al
    Prognostic value of TGF-beta in lung cancer: systematic review and meta-analysis.
    BMC Cancer. 2019;19:691.
    PubMed     Abstract available

  179. SONG J, Wang W, Wang Y, Qin Y, et al
    Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma.
    BMC Cancer. 2019;19:680.
    PubMed     Abstract available

  180. ZHANG Y, Sun L, Gao X, Guo A, et al
    RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma.
    BMC Cancer. 2019;19:670.
    PubMed     Abstract available

    June 2019
  181. DUBAERE E, Goffaux M, Wanet M, Bihin B, et al
    Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
    BMC Cancer. 2019;19:639.
    PubMed     Abstract available

  182. ZHOU Y, Sinha S, Schwartz JL, Adami GR, et al
    A subtype of oral, laryngeal, esophageal, and lung, squamous cell carcinoma with high levels of TrkB-T1 neurotrophin receptor mRNA.
    BMC Cancer. 2019;19:607.
    PubMed     Abstract available

  183. BECK TN, Boumber YA, Aggarwal C, Pei J, et al
    Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer.
    BMC Cancer. 2019;19:603.
    PubMed     Abstract available

  184. LAI J, Yang H, Zhu Y, Ruan M, et al
    MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
    BMC Cancer. 2019;19:602.
    PubMed     Abstract available

  185. FANG W, Huang Y, Hong S, Zhang Z, et al
    EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
    BMC Cancer. 2019;19:595.
    PubMed     Abstract available

  186. SHANG X, Liu J, Li Z, Lin J, et al
    A hypothesized TNM staging system based on the number and location of positive lymph nodes may better reflect the prognosis for patients with NSCLC.
    BMC Cancer. 2019;19:591.
    PubMed     Abstract available

  187. ANDRIES V, De Keuckelaere E, Staes K, Hochepied T, et al
    A new mouse model to study the role of ectopic Nanos3 expression in cancer.
    BMC Cancer. 2019;19:598.
    PubMed     Abstract available

  188. XU M, Wang X, Pan Y, Zhao X, et al
    Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
    BMC Cancer. 2019;19:599.
    PubMed     Abstract available

  189. GE J, Yao B, Huang J, Wu X, et al
    Molecular genetic characterization reveals linear tumor evolution in a pulmonary sarcomatoid carcinomas patient with a novel PHF20-NTRK1 fusion: a case report.
    BMC Cancer. 2019;19:592.
    PubMed     Abstract available

  190. CHEN G, Dong B, Shan G, Zhang X, et al
    Choice of immobilization of stereotactic body radiotherapy in lung tumor patient by BMI.
    BMC Cancer. 2019;19:583.
    PubMed     Abstract available

  191. KANG G, Chen K, Yang F, Chuai S, et al
    Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study.
    BMC Cancer. 2019;19:579.
    PubMed     Abstract available

  192. PARK JY, Jang SH, Kim HI, Kim JH, et al
    Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
    BMC Cancer. 2019;19:574.
    PubMed     Abstract available

  193. CALLEBOUT E, Ribeiro SM, Laurent S, De Man M, et al
    Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    BMC Cancer. 2019;19:567.
    PubMed     Abstract available

  194. KAREDATH T, Ahmed I, Al Ameri W, Al-Dasim FM, et al
    Silencing of ANKRD12 circRNA induces molecular and functional changes associated with invasive phenotypes.
    BMC Cancer. 2019;19:565.
    PubMed     Abstract available

  195. KOSAKA T, Hongo H, Oya M
    Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    BMC Cancer. 2019;19:562.
    PubMed     Abstract available

  196. SUN X, Roudi R, Dai T, Chen S, et al
    Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    BMC Cancer. 2019;19:558.
    PubMed     Abstract available

  197. TSUNODA A, Morikawa K, Inoue T, Miyazawa T, et al
    A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
    BMC Cancer. 2019;19:546.
    PubMed     Abstract available

    May 2019
  198. MIURA S, Naito T, Mitsunaga S, Omae K, et al
    A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol.
    BMC Cancer. 2019;19:528.
    PubMed     Abstract available

  199. KETTUNEN E, Savukoski S, Salmenkivi K, Bohling T, et al
    CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
    BMC Cancer. 2019;19:507.
    PubMed     Abstract available

  200. BHAT GR, Bhat A, Verma S, Sethi I, et al
    Association of newly identified genetic variant rs2853677 of TERT with non-small cell lung cancer and leukemia in population of Jammu and Kashmir, India.
    BMC Cancer. 2019;19:493.
    PubMed     Abstract available

  201. WANG W, Men Y, Wang J, Zhou Z, et al
    Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy.
    BMC Cancer. 2019;19:478.
    PubMed     Abstract available

  202. VAN NEST SJ, Nicholson LM, Pavey N, Hindi MN, et al
    Raman spectroscopy detects metabolic signatures of radiation response and hypoxic fluctuations in non-small cell lung cancer.
    BMC Cancer. 2019;19:474.
    PubMed     Abstract available

  203. YU L, Tao G, Zhu L, Wang G, et al
    Prediction of pathologic stage in non-small cell lung cancer using machine learning algorithm based on CT image feature analysis.
    BMC Cancer. 2019;19:464.
    PubMed     Abstract available

  204. BAI H, Wang C, Qi Y, Xu J, et al
    Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway.
    BMC Cancer. 2019;19:454.
    PubMed     Abstract available

  205. VISSER S, Hou J, Bezemer K, de Vogel LL, et al
    Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles.
    BMC Cancer. 2019;19:440.
    PubMed     Abstract available

  206. ZHAO F, Zhen FX, Zhou Y, Huang CJ, et al
    Clinicopathologic predictors of metastasis of different regional lymph nodes in patients intraoperatively diagnosed with stage-I non-small cell lung cancer.
    BMC Cancer. 2019;19:444.
    PubMed     Abstract available

  207. KHADDOUR K, Singh V, Shayuk M
    Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review.
    BMC Cancer. 2019;19:449.
    PubMed     Abstract available

  208. ZAHN MO, Linck D, Losem C, Gessner C, et al
    AVAiLABLE NIS - AVASTIN(R) in lung cancer treatment in routine oncology practice in Germany.
    BMC Cancer. 2019;19:433.
    PubMed     Abstract available

  209. SUWINSKI R, Giglok M, Galwas-Kliber K, Idasiak A, et al
    Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer.
    BMC Cancer. 2019;19:427.
    PubMed     Abstract available

  210. EICHHORN F, Klotz LV, Bischoff H, Thomas M, et al
    Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    BMC Cancer. 2019;19:413.
    PubMed     Abstract available

    April 2019
  211. DEL RE M, Rofi E, Cappelli C, Puppo G, et al
    The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report.
    BMC Cancer. 2019;19:410.
    PubMed     Abstract available

  212. D'ALMEIDA PRETO D, Baston MT, Geraige CC, Augusto SB, et al
    Impact of AferBio(R) on quality of life and chemotherapy toxicity in advanced lung cancer patients (AFERBIO study): protocol study for a phase II randomized controlled trial.
    BMC Cancer. 2019;19:382.
    PubMed     Abstract available

  213. CONNOCK M, Armoiry X, Tsertsvadze A, Melendez-Torres GJ, et al
    Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and sec
    BMC Cancer. 2019;19:392.
    PubMed     Abstract available

  214. NAGAMATSU Y, Oze I, Aoe K, Hotta K, et al
    Physician requests by patients with malignant pleural mesothelioma in Japan.
    BMC Cancer. 2019;19:383.
    PubMed     Abstract available

  215. BECK TN, Kudinov AE, Dulaimi E, Boumber Y, et al
    Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    BMC Cancer. 2019;19:379.
    PubMed     Abstract available

  216. GUO L, Chen Z, Xu C, Zhang X, et al
    Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level.
    BMC Cancer. 2019;19:369.
    PubMed     Abstract available

  217. VICKERS AD, Winfree KB, Cuyun Carter G, Kiiskinen U, et al
    Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2019;19:353.
    PubMed     Abstract available

  218. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Horlings HM, et al
    A specific gene expression signature for visceral organ metastasis in breast cancer.
    BMC Cancer. 2019;19:333.
    PubMed     Abstract available

  219. KURODA A, Tabuchi T, Iwami E, Sasahara K, et al
    Abscopal effect of radiation on multiple lung metastases of lung adenocarcinoma: a case report.
    BMC Cancer. 2019;19:336.
    PubMed     Abstract available

  220. SUMODHEE S, Bondiau PY, Poudenx M, Cohen C, et al
    Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer.
    BMC Cancer. 2019;19:305.
    PubMed     Abstract available

  221. FURUGAKI K, Mochizuki M, Kohno M, Shu S, et al
    Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    BMC Cancer. 2019;19:301.
    PubMed     Abstract available

  222. CHO YJ, Cho YM, Kim SH, Shin KH, et al
    Clinical analysis of patients with skeletal metastasis of lung cancer.
    BMC Cancer. 2019;19:303.
    PubMed     Abstract available

  223. WANG L, Meng Y, Zhang QY
    LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR.
    BMC Cancer. 2019;19:293.
    PubMed     Abstract available

    March 2019
  224. CHEN Y, Tsang YS, Chou X, Hu J, et al
    A lung cancer patient with deep vein thrombosis:a case report and literature review.
    BMC Cancer. 2019;19:285.
    PubMed     Abstract available

  225. YING J, Zhou D, Gu T, Huang J, et al
    Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
    BMC Cancer. 2019;19:288.
    PubMed     Abstract available

  226. GUO CY, Zhu Q, Tou FF, Wen XM, et al
    The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
    BMC Cancer. 2019;19:289.
    PubMed     Abstract available

  227. ZHAO P, Wu J, Lu F, Peng X, et al
    Correction to: The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer.
    BMC Cancer. 2019;19:269.
    PubMed     Abstract available

  228. YANG LH, Han Y, Li G, Xu HT, et al
    Correction to: Axin gene methylation status correlates with radiosensitivity of lung cancer cells.
    BMC Cancer. 2019;19:268.
    PubMed     Abstract available

  229. YU J, Hu Y, Xu Y, Wang J, et al
    LUADpp: an effective prediction model on prognosis of lung adenocarcinomas based on somatic mutational features.
    BMC Cancer. 2019;19:263.
    PubMed     Abstract available

  230. SONE K, Oguri T, Uemura T, Takeuchi A, et al
    Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort.
    BMC Cancer. 2019;19:246.
    PubMed     Abstract available

  231. SHIBUTANI M, Maeda K, Nagahara H, Fukuoka T, et al
    The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study.
    BMC Cancer. 2019;19:241.
    PubMed     Abstract available

  232. ZHANG C, Mao M, Guo X, Cui P, et al
    Nomogram based on homogeneous and heterogeneous associated factors for predicting bone metastases in patients with different histological types of lung cancer.
    BMC Cancer. 2019;19:238.
    PubMed     Abstract available

  233. ZHAO J, Teng H, Zhao R, Ding W, et al
    Malignant perivascular epithelioid cell tumor of the lung synchronous with a primary adenocarcinoma: one case report and review of the literature.
    BMC Cancer. 2019;19:235.
    PubMed     Abstract available

  234. ESFANDI F, Taheri M, Omrani MD, Shadmehr MB, et al
    Expression of long non-coding RNAs (lncRNAs) has been dysregulated in non-small cell lung cancer tissues.
    BMC Cancer. 2019;19:222.
    PubMed     Abstract available

  235. WOOD R, Taylor-Stokes G
    Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage.
    BMC Cancer. 2019;19:214.
    PubMed     Abstract available

  236. LU L, Liu Q, Wang P, Wu Y, et al
    MicroRNA-148b regulates tumor growth of non-small cell lung cancer through targeting MAPK/JNK pathway.
    BMC Cancer. 2019;19:209.
    PubMed     Abstract available

  237. ZHAO P, Wu J, Lu F, Peng X, et al
    The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer.
    BMC Cancer. 2019;19:201.
    PubMed     Abstract available

    February 2019
  238. NUKII Y, Miyamoto A, Mochizuki S, Moriguchi S, et al
    Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case report.
    BMC Cancer. 2019;19:186.
    PubMed     Abstract available

  239. NAMBA K, Tomida S, Matsubara T, Takahashi Y, et al
    Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naive lung adenocarcinoma.
    BMC Cancer. 2019;19:175.
    PubMed     Abstract available

  240. KLEMENT RJ, Abbasi-Senger N, Adebahr S, Alheid H, et al
    The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.
    BMC Cancer. 2019;19:173.
    PubMed     Abstract available

  241. BERGAMINO M, Rullan AJ, Saigi M, Peiro I, et al
    Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    BMC Cancer. 2019;19:165.
    PubMed     Abstract available

  242. SHIRASAWA M, Fukui T, Kusuhara S, Hiyoshi Y, et al
    Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
    BMC Cancer. 2019;19:163.
    PubMed     Abstract available

  243. LI WY, Zhao TT, Xu HM, Wang ZN, et al
    The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:145.
    PubMed     Abstract available

  244. KANG N, Choi SY, Kim BN, Yeo CD, et al
    Hypoxia-induced cancer stemness acquisition is associated with CXCR4 activation by its aberrant promoter demethylation.
    BMC Cancer. 2019;19:148.
    PubMed     Abstract available

  245. GE M, Zhan Q, Zhang Z, Ji X, et al
    Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases.
    BMC Cancer. 2019;19:143.
    PubMed     Abstract available

  246. D'ALMEIDA O, Mothar O, Bondzie EA, Lieumo Y, et al
    Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells.
    BMC Cancer. 2019;19:136.
    PubMed     Abstract available

  247. WANG J, Chen J
    Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
    BMC Cancer. 2019;19:131.
    PubMed     Abstract available

    January 2019
  248. BORCHERT S, Wessolly M, Schmeller J, Mairinger E, et al
    Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
    BMC Cancer. 2019;19:108.
    PubMed     Abstract available

  249. IMAKITA T, Matsumoto H, Hirano K, Morisawa T, et al
    Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review.
    BMC Cancer. 2019;19:105.
    PubMed     Abstract available

  250. YIN X, Yan D, Qiu M, Huang L, et al
    Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:95.
    PubMed     Abstract available

  251. CEA SORIANO L, Zong J, Garcia Rodriguez LA
    Feasibility and validity of The Health Improvement Network database of primary care electronic health records to identify and characterise patients with small cell lung cancer in the United Kingdom.
    BMC Cancer. 2019;19:91.
    PubMed     Abstract available

  252. ROMINE PE, Martins RG, Eaton KD, Wood DE, et al
    Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.
    BMC Cancer. 2019;19:70.
    PubMed     Abstract available

  253. HABEL N, Stefanovska B, Carene D, Patino-Garcia A, et al
    CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rbeta-dependent EMT-like process.
    BMC Cancer. 2019;19:62.
    PubMed     Abstract available

  254. LI M, Li H, Hong G, Tang Z, et al
    Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings.
    BMC Cancer. 2019;19:67.
    PubMed     Abstract available

  255. ABE M, Watanabe K, Shinozaki-Ushiku A, Ushiku T, et al
    Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review.
    BMC Cancer. 2019;19:52.
    PubMed     Abstract available

  256. CASSIM S, Chepulis L, Keenan R, Kidd J, et al
    Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review.
    BMC Cancer. 2019;19:25.
    PubMed     Abstract available

  257. YAN S, Sun R, Wu S, Jin T, et al
    Single nucleotide polymorphism in the 3' untranslated region of LPP is a risk factor for lung cancer: a case-control study.
    BMC Cancer. 2019;19:35.
    PubMed     Abstract available

  258. SIRIWARDHANA C, Khadka VS, Chen JJ, Deng Y, et al
    Development of a miRNA-seq based prognostic signature in lung adenocarcinoma.
    BMC Cancer. 2019;19:34.
    PubMed     Abstract available

  259. KIM R, Keam B, Kim S, Kim M, et al
    Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    BMC Cancer. 2019;19:19.
    PubMed     Abstract available

  260. WU Z, Wang Q, Wu C, Zhan T, et al
    Three-port single-intercostal versus multiple-intercostal thoracoscopic lobectomy for the treatment of lung cancer: a propensity-matched analysis.
    BMC Cancer. 2019;19:8.
    PubMed     Abstract available

  261. WERUTSKY G, Hochhegger B, Lopes de Figueiredo Pinto JA, Martinez-Mesa J, et al
    PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114).
    BMC Cancer. 2019;19:5.
    PubMed     Abstract available

    December 2018
  262. GUO HQ, Jia J, Zhao LL, Zhao H, et al
    Application of Ventana immunocytochemical analysis on ThinPrep cytology slides for detection of ALK rearrangement in patients with advanced non-small-cell lung cancer.
    BMC Cancer. 2018;18:1277.
    PubMed     Abstract available

  263. REMEN T, Pintos J, Abrahamowicz M, Siemiatycki J, et al
    Risk of lung cancer in relation to various metrics of smoking history: a case-control study in Montreal.
    BMC Cancer. 2018;18:1275.
    PubMed     Abstract available

  264. SUN H, Gao D
    Propofol suppresses growth, migration and invasion of A549 cells by down-regulation of miR-372.
    BMC Cancer. 2018;18:1252.
    PubMed     Abstract available

  265. YOSHIMURA A, Yamada T, Okura N, Takeda T, et al
    The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2018;18:1241.
    PubMed     Abstract available

  266. TSUTANI Y, Miyata Y, Masuda T, Fujitaka K, et al
    Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
    BMC Cancer. 2018;18:1231.
    PubMed     Abstract available

  267. NG KEE KWONG F, Nicholson AG, Pavlidis S, Adcock IM, et al
    PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).
    BMC Cancer. 2018;18:1238.
    PubMed     Abstract available

  268. HUANG Y, Wei S, Jiang N, Zhang L, et al
    The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:1235.
    PubMed     Abstract available

  269. LEE JS, Hur JY, Kim IA, Kim HJ, et al
    Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
    BMC Cancer. 2018;18:1236.
    PubMed     Abstract available

  270. KIM EY, Kim A, Lee G, Lee H, et al
    Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma.
    BMC Cancer. 2018;18:1221.
    PubMed     Abstract available

  271. TAN WL, Ng QS, Lim C, Tan EH, et al
    Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    BMC Cancer. 2018;18:1198.
    PubMed     Abstract available

    November 2018
  272. SINGH AK, Hennon M, Ma SJ, Demmy TL, et al
    A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer.
    BMC Cancer. 2018;18:1183.
    PubMed     Abstract available

  273. SCHWARTZ RM, Lieberman-Cribbin W, Wolf A, Flores RM, et al
    Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma.
    BMC Cancer. 2018;18:1188.
    PubMed     Abstract available

  274. LIU K, Xu SH, Chen Z, Zeng QX, et al
    TRPM7 overexpression enhances the cancer stem cell-like and metastatic phenotypes of lung cancer through modulation of the Hsp90alpha/uPA/MMP2 signaling pathway.
    BMC Cancer. 2018;18:1167.
    PubMed     Abstract available

  275. CHEN RL, Zhao J, Zhang XC, Lou NN, et al
    Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    BMC Cancer. 2018;18:1171.
    PubMed     Abstract available

  276. DE MOL M, Visser S, Aerts JGJV, Lodder P, et al
    Satisfactory results of a psychometric analysis and calculation of minimal clinically important differences of the World Health Organization quality of life-BREF questionnaire in an observational cohort study with lung cancer and mesothelioma patients
    BMC Cancer. 2018;18:1173.
    PubMed     Abstract available

  277. VOLLBRECHT C, Lenze D, Hummel M, Lehmann A, et al
    RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
    BMC Cancer. 2018;18:1158.
    PubMed     Abstract available

  278. RICH A, Baldwin D, Alfageme I, Beckett P, et al
    Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries.
    BMC Cancer. 2018;18:1144.
    PubMed     Abstract available

  279. JIN B, Zhang S, Chuang X, Yu P, et al
    Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report.
    BMC Cancer. 2018;18:1138.
    PubMed     Abstract available

  280. YOSHIDA R, Sasaki T, Umekage Y, Tanno S, et al
    Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR.
    BMC Cancer. 2018;18:1136.
    PubMed     Abstract available

  281. ZANELLI M, Mengoli MC, Del Sordo R, Cagini A, et al
    Intravascular NK/T-cell lymphoma, Epstein-Barr virus positive with multiorgan involvement: a clinical dilemma.
    BMC Cancer. 2018;18:1115.
    PubMed     Abstract available

  282. SEIGNEURIN A, Delafosse P, Tretarre B, Woronoff AS, et al
    Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries.
    BMC Cancer. 2018;18:1091.
    PubMed     Abstract available

  283. KIM EJ, Ock M, Kim KP, Jung NH, et al
    Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea.
    BMC Cancer. 2018;18:1081.
    PubMed     Abstract available

  284. PU X, Wu L, Su D, Mao W, et al
    Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance.
    BMC Cancer. 2018;18:1082.
    PubMed     Abstract available

  285. WANG X, Yin C, Su S, Li X, et al
    Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis.
    BMC Cancer. 2018;18:1067.
    PubMed     Abstract available

  286. ZHENG LP, Chen LY, Liao XY, Xu ZH, et al
    Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation.
    BMC Cancer. 2018;18:1070.
    PubMed     Abstract available

    October 2018
  287. YI YS, Ban WH, Sohng KY
    Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer.
    BMC Cancer. 2018;18:1053.
    PubMed     Abstract available

  288. IEZZI A, Caiola E, Scagliotti A, Broggini M, et al
    Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells.
    BMC Cancer. 2018;18:1028.
    PubMed     Abstract available

  289. ZHOU F, Ma W, Li W, Ni H, et al
    Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
    BMC Cancer. 2018;18:1033.
    PubMed     Abstract available

  290. SCHERPEREEL A, Durand-Zaleski I, Cotte FE, Fernandes J, et al
    Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.
    BMC Cancer. 2018;18:1013.
    PubMed     Abstract available

  291. AIKO N, Shimokawa T, Miyazaki K, Misumi Y, et al
    Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2018;18:1012.
    PubMed     Abstract available

  292. LAVACCHI D, Nobili S, Brugia M, Paderi A, et al
    A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma.
    BMC Cancer. 2018;18:1024.
    PubMed     Abstract available

  293. HAI Y, Chen N, Wu W, Wang Z, et al
    High postoperative monocyte indicates inferior Clinicopathological characteristics and worse prognosis in lung adenocarcinoma or squamous cell carcinoma after lobectomy.
    BMC Cancer. 2018;18:1011.
    PubMed     Abstract available

  294. GUO Y, Wang X, Xiao J, Xu Y, et al
    Lung squamous cell carcinoma with solitary ocular metastasis and its successful treatment with thoracic surgery and chemotherapy: an interesting and rare case report.
    BMC Cancer. 2018;18:1004.
    PubMed     Abstract available

  295. XU J, Guo W, Xie L
    Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
    BMC Cancer. 2018;18:987.
    PubMed     Abstract available

  296. KIM MK, Yee J, Cho YS, Jang HW, et al
    Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
    BMC Cancer. 2018;18:988.
    PubMed     Abstract available

  297. LIU L, Shi M, Wang Z, Lu H, et al
    A molecular and staging model predicts survival in patients with resected non-small cell lung cancer.
    BMC Cancer. 2018;18:966.
    PubMed     Abstract available

  298. QIN RS, Zhang ZH, Zhu NP, Chen F, et al
    Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma.
    BMC Cancer. 2018;18:967.
    PubMed     Abstract available

  299. WANG X, Zamdborg L, Ye H, Grills IS, et al
    A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.
    BMC Cancer. 2018;18:962.
    PubMed     Abstract available

  300. ISAKA T, Nakayama H, Ito H, Yokose T, et al
    Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
    BMC Cancer. 2018;18:959.
    PubMed     Abstract available

  301. TACHIHARA M, Negoro S, Inoue T, Tamiya M, et al
    Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
    BMC Cancer. 2018;18:946.
    PubMed     Abstract available

  302. SABATH B, Muhammad HA, Balagani A, Ost DE, et al
    Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.
    BMC Cancer. 2018;18:937.
    PubMed     Abstract available

    September 2018
  303. MIKKELSEN MK, Lund CM, Vinther A, Tolver A, et al
    Engaging the older cancer patient; Patient Activation through Counseling, Exercise and Mobilization - Pancreatic, Biliary tract and Lung cancer (PACE-Mobil-PBL) - study protocol of a randomized controlled trial.
    BMC Cancer. 2018;18:934.
    PubMed     Abstract available

  304. ANDRIANI F, Landoni E, Mensah M, Facchinetti F, et al
    Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer.
    BMC Cancer. 2018;18:899.
    PubMed     Abstract available

  305. YIN Z, Cui Z, Li H, Li J, et al
    Polymorphisms in the H19 gene and the risk of lung Cancer among female never smokers in Shenyang, China.
    BMC Cancer. 2018;18:893.
    PubMed     Abstract available

  306. BENBRAHIM Z, Antonia T, Mellas N
    EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:891.
    PubMed     Abstract available

  307. VANHOVE K, Giesen P, Owokotomo OE, Mesotten L, et al
    The plasma glutamate concentration as a complementary tool to differentiate benign PET-positive lung lesions from lung cancer.
    BMC Cancer. 2018;18:868.
    PubMed     Abstract available

    August 2018
  308. KIM Y, Pierce CM, Robinson LA
    Impact of viral presence in tumor on gene expression in non-small cell lung cancer.
    BMC Cancer. 2018;18:843.
    PubMed     Abstract available

  309. FUMET JD, Wickre M, Jacquot JP, Bizollon MH, et al
    Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer.
    BMC Cancer. 2018;18:839.
    PubMed     Abstract available

  310. URUGA H, Moriguchi S, Takahashi Y, Ogawa K, et al
    Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
    BMC Cancer. 2018;18:825.
    PubMed     Abstract available

  311. VAUGHN CP, Costa JL, Feilotter HE, Petraroli R, et al
    Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.
    BMC Cancer. 2018;18:828.
    PubMed     Abstract available

  312. KIM MC, Hwang SH, Kim NY, Lee HS, et al
    Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma.
    BMC Cancer. 2018;18:819.
    PubMed     Abstract available

  313. XU F, Ren X, Chen Y, Li Q, et al
    Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
    BMC Cancer. 2018;18:808.
    PubMed     Abstract available

  314. HUANG H, Tong TT, Yau LF, Chen CY, et al
    LC-MS based sphingolipidomic study on A549 human lung adenocarcinoma cell line and its taxol-resistant strain.
    BMC Cancer. 2018;18:799.
    PubMed     Abstract available

  315. KORDOWSKI F, Kolarova J, Schafmayer C, Buch S, et al
    Aberrant DNA methylation of ADAMTS16 in colorectal and other epithelial cancers.
    BMC Cancer. 2018;18:796.
    PubMed     Abstract available

  316. ZHANG W, Wei Y, Yu D, Xu J, et al
    Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
    BMC Cancer. 2018;18:780.
    PubMed     Abstract available

    July 2018
  317. KIM IA, Lee JS, Kim HJ, Kim WS, et al
    Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.
    BMC Cancer. 2018;18:768.
    PubMed     Abstract available

  318. SAHIN IH, Elias H, Chou JF, Capanu M, et al
    Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior.
    BMC Cancer. 2018;18:769.
    PubMed     Abstract available

  319. BORM KJ, Oechsner M, Wiegandt M, Hofmeister A, et al
    Moving targets in 4D-CTs versus MIP and AIP: comparison of patients data to phantom data.
    BMC Cancer. 2018;18:760.
    PubMed     Abstract available

  320. BUTCHER K, Kannappan V, Kilari RS, Morris MR, et al
    Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line.
    BMC Cancer. 2018;18:753.
    PubMed     Abstract available

  321. MAZZA D, Lin X, Walter FM, Young JM, et al
    The LEAD study protocol: a mixed-method cohort study evaluating the lung cancer diagnostic and pre-treatment pathways of patients from Culturally and Linguistically Diverse (CALD) backgrounds compared to patients from Anglo-Australian backgrounds.
    BMC Cancer. 2018;18:754.
    PubMed     Abstract available

  322. BERG J, Halvorsen AR, Bengtson MB, Tasken KA, et al
    Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease.
    BMC Cancer. 2018;18:739.
    PubMed     Abstract available

  323. ZACHARIAS M, Brcic L, Eidenhammer S, Popper H, et al
    Bulk tumour cell migration in lung carcinomas might be more common than epithelial-mesenchymal transition and be differently regulated.
    BMC Cancer. 2018;18:717.
    PubMed     Abstract available

  324. SHENG Y, Xu M, Li C, Xiong Y, et al
    Nm23-H1 is involved in the repair of ionizing radiation-induced DNA double-strand breaks in the A549 lung cancer cell line.
    BMC Cancer. 2018;18:710.
    PubMed     Abstract available

    June 2018
  325. WANG Y, Qu X, Kam NW, Wang K, et al
    An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy.
    BMC Cancer. 2018;18:692.
    PubMed     Abstract available

  326. LI X, Zhou Q, Wang X, Su S, et al
    The effect of low insurance reimbursement on quality of care for non-small cell lung cancer in China: a comprehensive study covering diagnosis, treatment, and outcomes.
    BMC Cancer. 2018;18:683.
    PubMed     Abstract available

  327. TIAN X, Ma J, Wang T, Tian J, et al
    Long non-coding RNA RUNXOR accelerates MDSC-mediated immunosuppression in lung cancer.
    BMC Cancer. 2018;18:660.
    PubMed     Abstract available

  328. HOU X, Gong R, Zhan J, Zhou T, et al
    p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells.
    BMC Cancer. 2018;18:641.
    PubMed     Abstract available

  329. ZHU H, Zhang S
    Body mass index and lung cancer risk in never smokers: a meta-analysis.
    BMC Cancer. 2018;18:635.
    PubMed     Abstract available

    May 2018
  330. MARINGE C, Pashayan N, Rubio FJ, Ploubidis G, et al
    Trends in lung cancer emergency presentation in England, 2006-2013: is there a pattern by general practice?
    BMC Cancer. 2018;18:615.
    PubMed     Abstract available

  331. SHINOZAKI T, Iwami E, Ikemura S, Matsuzaki T, et al
    A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy.
    BMC Cancer. 2018;18:620.
    PubMed     Abstract available

  332. ZENG J, Zhang H, Tan Y, Sun C, et al
    Aggregation of lipid rafts activates c-met and c-Src in non-small cell lung cancer cells.
    BMC Cancer. 2018;18:611.
    PubMed     Abstract available

  333. ZHENG J, Jia L, Mori S, Kodama T, et al
    Evaluation of metastatic niches in distant organs after surgical removal of tumor-bearing lymph nodes.
    BMC Cancer. 2018;18:608.
    PubMed     Abstract available

  334. WEI X, Zhang K, Qin H, Zhu J, et al
    GMDS knockdown impairs cell proliferation and survival in human lung adenocarcinoma.
    BMC Cancer. 2018;18:600.
    PubMed     Abstract available

  335. MARKOCZY Z, Sarosi V, Kudaba I, Galffy G, et al
    Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
    BMC Cancer. 2018;18:598.
    PubMed     Abstract available

  336. LI H, Huang N, Zhu W, Wu J, et al
    Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2.
    BMC Cancer. 2018;18:579.
    PubMed     Abstract available

  337. ZHOU W, Chen X, Hu Q, Chen X, et al
    Galectin-3 activates TLR4/NF-kappaB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression.
    BMC Cancer. 2018;18:580.
    PubMed     Abstract available

  338. BUCZEK E, Denslow A, Mateuszuk L, Proniewski B, et al
    Alterations in NO- and PGI2- dependent function in aorta in the orthotopic murine model of metastatic 4T1 breast cancer: relationship with pulmonary endothelial dysfunction and systemic inflammation.
    BMC Cancer. 2018;18:582.
    PubMed     Abstract available

  339. LIMVIPHUVADH V, Tan CS, Konishi F, Jenjaroenpun P, et al
    Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy.
    BMC Cancer. 2018;18:555.
    PubMed     Abstract available

  340. LI Y, Chen G, Chen H, Wen S, et al
    Spontaneous renal hemorrhage secondary to choriocarcinoma in a man with congenital hypospadias and cryptorchidism: a case report and literature review.
    BMC Cancer. 2018;18:543.
    PubMed     Abstract available

  341. EZZELDIN N, El-Lebedy D, Darwish A, El Bastawisy A, et al
    Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population.
    BMC Cancer. 2018;18:525.
    PubMed     Abstract available

  342. QUAIFE SL, Vrinten C, Ruparel M, Janes SM, et al
    Smokers' interest in a lung cancer screening programme: a national survey in England.
    BMC Cancer. 2018;18:497.
    PubMed     Abstract available

  343. DI GIROLAMO C, Walters S, Benitez Majano S, Rachet B, et al
    Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013.
    BMC Cancer. 2018;18:492.
    PubMed     Abstract available

    April 2018
  344. BLUM W, Pecze L, Rodriguez JW, Steinauer M, et al
    Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter.
    BMC Cancer. 2018;18:475.
    PubMed     Abstract available

  345. MORRISON BJ, Steel JC, Morris JC
    Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells.
    BMC Cancer. 2018;18:469.
    PubMed     Abstract available

  346. HE F, Xiao RD, Lin T, Xiong WM, et al
    Dietary patterns, BCMO1 polymorphisms, and primary lung cancer risk in a Han Chinese population: a case-control study in Southeast China.
    BMC Cancer. 2018;18:445.
    PubMed     Abstract available

  347. MISHRA DK, Miller RA, Pence KA, Kim MP, et al
    Small cell and non small cell lung cancer form metastasis on cellular 4D lung model.
    BMC Cancer. 2018;18:441.
    PubMed     Abstract available

  348. GIGER-PABST U, Demtroder C, Falkenstein TA, Ouaissi M, et al
    Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma.
    BMC Cancer. 2018;18:442.
    PubMed     Abstract available

  349. ABBAS HHK, Alhamoudi KMH, Evans MD, Jones GDD, et al
    MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
    BMC Cancer. 2018;18:423.
    PubMed     Abstract available

  350. DHONT L, Pintilie M, Kaufman E, Navab R, et al
    Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).
    BMC Cancer. 2018;18:429.
    PubMed     Abstract available

  351. AI X, Mao F, Shen S, Shentu Y, et al
    Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.
    BMC Cancer. 2018;18:407.
    PubMed     Abstract available

  352. HE W, Zhang H, Wang Y, Zhou Y, et al
    CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9.
    BMC Cancer. 2018;18:400.
    PubMed     Abstract available

  353. VANNIMENUS C, Bricout H, Le Rouzic O, Mouawad F, et al
    Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study.
    BMC Cancer. 2018;18:372.
    PubMed     Abstract available

  354. THRIUMANI R, Zakaria A, Hashim YZH, Jeffree AI, et al
    A study on volatile organic compounds emitted by in-vitro lung cancer cultured cells using gas sensor array and SPME-GCMS.
    BMC Cancer. 2018;18:362.
    PubMed     Abstract available

    March 2018
  355. TAN PT, Aziz MIA, Pearce F, Lim WT, et al
    Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    BMC Cancer. 2018;18:352.
    PubMed     Abstract available

  356. BRUECKL WM, Achenbach HJ, Ficker JH, Schuette W, et al
    Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
    BMC Cancer. 2018;18:333.
    PubMed     Abstract available

  357. NAGAMATSU Y, Oze I, Aoe K, Hotta K, et al
    Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.
    BMC Cancer. 2018;18:350.
    PubMed     Abstract available

  358. WANG Y, Zhang S, Wu F, Zhao J, et al
    Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
    BMC Cancer. 2018;18:326.
    PubMed     Abstract available

  359. MAMBETSARIEV I, Vora L, Yu KW, Salgia R, et al
    Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
    BMC Cancer. 2018;18:314.
    PubMed     Abstract available

  360. FIDLER MJ, Fhied CL, Roder J, Basu S, et al
    The serum-based VeriStrat(R) test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
    BMC Cancer. 2018;18:310.
    PubMed     Abstract available

  361. LYNCH JA, Berse B, Rabb M, Mosquin P, et al
    Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.
    BMC Cancer. 2018;18:306.
    PubMed     Abstract available

  362. HAKOZAKI T, Okuma Y, Kashima J
    Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report.
    BMC Cancer. 2018;18:302.
    PubMed     Abstract available

  363. BRIZZI MP, La Salvia A, Tampellini M, Sonetto C, et al
    Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review.
    BMC Cancer. 2018;18:311.
    PubMed     Abstract available

  364. YORITA K, Tsuji K, Takano Y, Kuroda N, et al
    Acantholytic squamous cell carcinoma of the lung with marked lymphogenous metastases and high titers of myeloperoxidase-antineutrophil cytoplasmic antibodies: a case report.
    BMC Cancer. 2018;18:300.
    PubMed     Abstract available

  365. TAI LH, Ananth AA, Seth R, Alkayyal A, et al
    Sepsis increases perioperative metastases in a murine model.
    BMC Cancer. 2018;18:277.
    PubMed     Abstract available

  366. YAO D, Zhang L, Wu PL, Gu XL, et al
    Clinical and misdiagnosed analysis of primary pulmonary lymphoma: a retrospective study.
    BMC Cancer. 2018;18:281.
    PubMed     Abstract available

  367. RYSKA A, Berzinec P, Brcic L, Cufer T, et al
    NSCLC molecular testing in Central and Eastern European countries.
    BMC Cancer. 2018;18:269.
    PubMed     Abstract available

  368. WANG G, Guo C, Zhao H, Pan Z, et al
    TIPE3 differentially modulates proliferation and migration of human non-small-cell lung cancer cells via distinct subcellular location.
    BMC Cancer. 2018;18:260.
    PubMed     Abstract available

  369. JIN BF, Yang F, Ying XM, Gong L, et al
    Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.
    BMC Cancer. 2018;18:259.
    PubMed     Abstract available

  370. LEE DW, Lee KH, Kim HJ, Kim TY, et al
    A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
    BMC Cancer. 2018;18:252.
    PubMed     Abstract available

  371. IKEDA S, Kato T, Ogura T, Sekine A, et al
    Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thorac
    BMC Cancer. 2018;18:241.
    PubMed     Abstract available

    February 2018
  372. BROGDEN KA, Parashar D, Hallier AR, Braun T, et al
    Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
    BMC Cancer. 2018;18:225.
    PubMed     Abstract available

  373. SANIKINI H, Yuan JM, Butler LM, Koh WP, et al
    Body mass index and lung cancer risk: a pooled analysis based on nested case-control studies from four cohort studies.
    BMC Cancer. 2018;18:220.
    PubMed     Abstract available

  374. DE FONSEKA D, Arnold DT, Stadon L, Morley A, et al
    A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
    BMC Cancer. 2018;18:199.
    PubMed     Abstract available

  375. DEMUTH C, Madsen AT, Weber B, Wu L, et al
    The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
    BMC Cancer. 2018;18:191.
    PubMed     Abstract available

  376. CHU GCW, Lazare K, Sullivan F
    Serum and blood based biomarkers for lung cancer screening: a systematic review.
    BMC Cancer. 2018;18:181.
    PubMed     Abstract available

  377. KODAIRA M, Yonemori K, Shimoi T, Yoshida A, et al
    Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    BMC Cancer. 2018;18:176.
    PubMed     Abstract available

  378. OLIVIER C, Grosbois JM, Cortot AB, Peres S, et al
    Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.
    BMC Cancer. 2018;18:178.
    PubMed     Abstract available

  379. MERVAI Z, Egedi K, Kovalszky I, Baghy K, et al
    Diethylnitrosamine induces lung adenocarcinoma in FVB/N mouse.
    BMC Cancer. 2018;18:157.
    PubMed     Abstract available

  380. WANG ZF, Ren SX, Li W, Gao GH, et al
    Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:148.
    PubMed     Abstract available

  381. SCHUETTE W, Schirmacher P, Eberhardt WEE, Dietel M, et al
    Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
    BMC Cancer. 2018;18:135.
    PubMed     Abstract available

    January 2018
  382. OU JY, Fowler B, Ding Q, Kirchhoff AC, et al
    A statewide investigation of geographic lung cancer incidence patterns and radon exposure in a low-smoking population.
    BMC Cancer. 2018;18:115.
    PubMed     Abstract available

  383. ARRIOLA E, Garcia Gomez R, Diz P, Majem M, et al
    Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
    BMC Cancer. 2018;18:106.
    PubMed     Abstract available

  384. NARUMI Y, Yoshida R, Minami Y, Yamamoto Y, et al
    Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
    BMC Cancer. 2018;18:95.
    PubMed     Abstract available

  385. MOKHLES S, Nuyttens JJME, de Mol M, Aerts JGJV, et al
    Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making.
    BMC Cancer. 2018;18:79.
    PubMed     Abstract available

  386. WU N, Ren D, Li S, Ma W, et al
    RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation.
    BMC Cancer. 2018;18:67.
    PubMed     Abstract available

  387. HERNANDEZ RK, Wade SW, Reich A, Pirolli M, et al
    Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
    BMC Cancer. 2018;18:44.
    PubMed     Abstract available

  388. DEPCZYNSKI J, Dobbins T, Armstrong B, Lower T, et al
    Comparison of cancer incidence in Australian farm residents 45 years and over, compared to rural non-farm and urban residents - a data linkage study.
    BMC Cancer. 2018;18:33.
    PubMed     Abstract available

  389. QU TT, Chen F, Wang J, Zhang YJ, et al
    PCAF-mediated acetylation of Lin28B increases let-7 biogenesis in lung adenocarcinoma H1299 cells.
    BMC Cancer. 2018;18:27.
    PubMed     Abstract available

  390. ZHOU J, Zheng J, Zhang X, Zhao J, et al
    Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
    BMC Cancer. 2018;18:10.
    PubMed     Abstract available

  391. KANEDA T, Yoshioka H, Tamiya M, Tamiya A, et al
    Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    BMC Cancer. 2018;18:6.
    PubMed     Abstract available

    December 2017
  392. LIU D, Huang Y, Li L, Song J, et al
    High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer.
    BMC Cancer. 2017;17:882.
    PubMed     Abstract available

  393. WANG D, Haley JD, Thompson P
    Comparative gene co-expression network analysis of epithelial to mesenchymal transition reveals lung cancer progression stages.
    BMC Cancer. 2017;17:830.
    PubMed     Abstract available

  394. BLANCO-PRIETO S, Barcia-Castro L, Paez de la Cadena M, Rodriguez-Berrocal FJ, et al
    Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis.
    BMC Cancer. 2017;17:823.
    PubMed     Abstract available

    November 2017
  395. IKEDA S, Yoshioka H, Ikeo S, Morita M, et al
    Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.
    BMC Cancer. 2017;17:797.
    PubMed     Abstract available

  396. NAITO T, Okayama T, Aoyama T, Ohashi T, et al
    Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.
    BMC Cancer. 2017;17:800.
    PubMed     Abstract available

  397. HIGUCHI Y, Motoki T, Ishida H, Kanamitsu K, et al
    Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report.
    BMC Cancer. 2017;17:775.
    PubMed     Abstract available

  398. KRISHNASWAMY S, Mohammed AK, Tripathi G, Alokail MS, et al
    Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing.
    BMC Cancer. 2017;17:738.
    PubMed     Abstract available

  399. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Abstract available

  400. WANG T, Chen X, Qiao W, Kong L, et al
    Transcription factor E2F1 promotes EMT by regulating ZEB2 in small cell lung cancer.
    BMC Cancer. 2017;17:719.
    PubMed     Abstract available

    October 2017
  401. TANAKA H, Taima K, Morimoto T, Tanaka Y, et al
    A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
    BMC Cancer. 2017;17:683.
    PubMed     Abstract available

    September 2017
  402. EDBROOKE L, Aranda S, Granger CL, McDonald CF, et al
    Benefits of home-based multidisciplinary exercise and supportive care in inoperable non-small cell lung cancer - protocol for a phase II randomised controlled trial.
    BMC Cancer. 2017;17:663.
    PubMed     Abstract available

  403. JIN R, Chen X, Han D, Luo X, et al
    Clusterin modulates transdifferentiation of non-small-cell lung cancer.
    BMC Cancer. 2017;17:661.
    PubMed     Abstract available

  404. URUSHIYAMA H, Jo T, Yasunaga H, Yamauchi Y, et al
    Adjuvant chemotherapy versus chemoradiotherapy for small cell lung cancer with lymph node metastasis: a retrospective observational study with use of a national database in Japan.
    BMC Cancer. 2017;17:613.
    PubMed     Abstract available

    August 2017
  405. WANG X, Su S, Li S, Bao H, et al
    Development of quality indicators for non-small cell lung cancer care: a first step toward assessing and improving quality of cancer care in China.
    BMC Cancer. 2017;17:603.
    PubMed     Abstract available

  406. AARELEID T, Zimmermann ML, Baburin A, Innos K, et al
    Divergent trends in lung cancer incidence by gender, age and histological type in Estonia: a nationwide population-based study.
    BMC Cancer. 2017;17:596.
    PubMed     Abstract available

  407. PARK SM, Lee J, Kim YA, Chang YJ, et al
    Factors related with colorectal and stomach cancer screening practice among disease-free lung cancer survivors in Korea.
    BMC Cancer. 2017;17:600.
    PubMed     Abstract available

  408. HATA Y, Kiribayashi T, Kishi K, Nagashima M, et al
    Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
    BMC Cancer. 2017;17:581.
    PubMed     Abstract available

  409. NAITO T, Okayama T, Aoyama T, Ohashi T, et al
    Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer.
    BMC Cancer. 2017;17:571.
    PubMed     Abstract available

  410. SZTANKAY M, Giesinger JM, Zabernigg A, Krempler E, et al
    Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
    BMC Cancer. 2017;17:565.
    PubMed     Abstract available

  411. LEE YS, Nam HS, Lim JH, Kim JS, et al
    Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.
    BMC Cancer. 2017;17:557.
    PubMed     Abstract available

    July 2017
  412. FUGAZZARO S, Costi S, Mainini C, Kopliku B, et al
    PUREAIR protocol: randomized controlled trial of intensive pulmonary rehabilitation versus standard care in patients undergoing surgical resection for lung cancer.
    BMC Cancer. 2017;17:508.
    PubMed     Abstract available

  413. WANG Q, Cheng Y, Wang Y, Fan Y, et al
    Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
    BMC Cancer. 2017;17:492.
    PubMed     Abstract available

  414. KIM EY, Jung JY, Kim A, Kim K, et al
    Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer.
    BMC Cancer. 2017;17:467.
    PubMed     Abstract available

  415. ZHOU Q, Song Y, Zhang X, Chen GY, et al
    A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    BMC Cancer. 2017;17:462.
    PubMed     Abstract available

    June 2017
  416. RADWAN N, Phillips R, Ross A, Rowe SP, et al
    A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    BMC Cancer. 2017;17:453.
    PubMed     Abstract available

  417. SNEDDON S, Patch AM, Dick IM, Kazakoff S, et al
    Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.
    BMC Cancer. 2017;17:396.
    PubMed     Abstract available

    May 2017
  418. JOHNEN G, Gawrych K, Raiko I, Casjens S, et al
    Calretinin as a blood-based biomarker for mesothelioma.
    BMC Cancer. 2017;17:386.
    PubMed     Abstract available

  419. MISUMI Y, Okamoto H, Sasaki J, Masuda N, et al
    Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
    BMC Cancer. 2017;17:377.
    PubMed     Abstract available

  420. KULASINGHE A, Perry C, Kenny L, Warkiani ME, et al
    PD-L1 expressing circulating tumour cells in head and neck cancers.
    BMC Cancer. 2017;17:333.
    PubMed     Abstract available

  421. GAMBICHLER T, Strutzmann S, Tannapfel A, Susok L, et al
    Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
    BMC Cancer. 2017;17:327.
    PubMed     Abstract available

  422. YEO J, Crawford EL, Zhang X, Khuder S, et al
    A lung cancer risk classifier comprising genome maintenance genes measured in normal bronchial epithelial cells.
    BMC Cancer. 2017;17:301.
    PubMed     Abstract available

  423. NAKAMURA K, Kato M, Shukuya T, Mori K, et al
    Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
    BMC Cancer. 2017;17:302.
    PubMed     Abstract available

  424. SHIMAZU K, Tada Y, Morinaga T, Shingyoji M, et al
    Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
    BMC Cancer. 2017;17:309.
    PubMed     Abstract available

  425. TAYLOR SA, Mallett S, Miles A, Beare S, et al
    Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L).
    BMC Cancer. 2017;17:299.
    PubMed     Abstract available

    April 2017
  426. OHSAKI Y, Sasaki T, Endo S, Kitada M, et al
    Observation of Zn-photoprotoporphyrin red Autofluorescence in human bronchial cancer using color-fluorescence endoscopy.
    BMC Cancer. 2017;17:289.
    PubMed     Abstract available

  427. ZHOU T, Zhan J, Fang W, Zhao Y, et al
    Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC).
    BMC Cancer. 2017;17:269.
    PubMed     Abstract available

  428. ZHAO F, Zhou Y, Ge PF, Huang CJ, et al
    A prediction model for lymph node metastases using pathologic features in patients intraoperatively diagnosed as stage I non-small cell lung cancer.
    BMC Cancer. 2017;17:267.
    PubMed     Abstract available

  429. HORIMASU Y, Ishikawa N, Tanaka S, Hirano C, et al
    MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study.
    BMC Cancer. 2017;17:263.
    PubMed     Abstract available

  430. YANG X, Pei S, Wang H, Jin Y, et al
    Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73.
    BMC Cancer. 2017;17:255.
    PubMed     Abstract available

  431. LI MX, He H, Ruan ZH, Zhu YX, et al
    Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    BMC Cancer. 2017;17:245.
    PubMed     Abstract available

    March 2017
  432. FRUGTNIET BA, Martin TA, Zhang L, Jiang WG, et al
    Neural Wiskott-Aldrich syndrome protein (nWASP) is implicated in human lung cancer invasion.
    BMC Cancer. 2017;17:224.
    PubMed     Abstract available

  433. AK G, Tada Y, Shimada H, Metintas S, et al
    Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    BMC Cancer. 2017;17:212.
    PubMed     Abstract available

  434. BHANGOO MS, Zhou JY, Ali SM, Madison R, et al
    Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report.
    BMC Cancer. 2017;17:197.
    PubMed     Abstract available

  435. WANG JZ, Xiang JJ, Wu LG, Bai YS, et al
    A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis.
    BMC Cancer. 2017;17:167.
    PubMed     Abstract available

    February 2017
  436. FERNANDEZ-MARTINEZ L, Villegas JA, Santamaria I, Pitiot AS, et al
    Identification of somatic and germ-line DICER1 mutations in pleuropulmonary blastoma, cystic nephroma and rhabdomyosarcoma tumors within a DICER1 syndrome pedigree.
    BMC Cancer. 2017;17:146.
    PubMed     Abstract available

  437. MA J, Yang QL, Ling Y
    Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
    BMC Cancer. 2017;17:132.
    PubMed     Abstract available

  438. MEDENWALD D, Vordermark D, Dietzel CT
    Cancer mortality in former East and West Germany: a story of unification?
    BMC Cancer. 2017;17:94.
    PubMed     Abstract available

    January 2017
  439. WANG L, Liu D, Lu J, Zhang S, et al
    The feasibility and advantage of uniportal video-assisted thoracoscopic surgery (VATS) in pulmonary lobectomy.
    BMC Cancer. 2017;17:75.
    PubMed     Abstract available

  440. VALTCHEVA N, Lang FM, Noske A, Samartzis EP, et al
    Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
    BMC Cancer. 2017;17:66.
    PubMed     Abstract available

  441. GOTO T, Hirotsu Y, Mochizuki H, Nakagomi T, et al
    Stepwise addition of genetic changes correlated with histological change from "well-differentiated" to "sarcomatoid" phenotypes: a case report.
    BMC Cancer. 2017;17:65.
    PubMed     Abstract available

  442. PALSHOF JA, Hogdall EV, Poulsen TS, Linnemann D, et al
    Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
    BMC Cancer. 2017;17:48.
    PubMed     Abstract available

  443. MARRER E, Jolly D, Arveux P, Lejeune C, et al
    Incidence of solitary pulmonary nodules in Northeastern France: a population-based study in five regions.
    BMC Cancer. 2017;17:47.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.